Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic
  • Search Hotels in Pleasanton

  • ROOMS:

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland

  • BiondVax participated in the life science industry’s 17th annual Bio-Europe Spring Conference, held this year in Switzerland
  • BiondVax was highlighted as one of the “best ideas” in a NASDAQ-published article after the completion of the conference
  • The company’s biobetter nanosized antibody therapies promise stability at high temperatures, superior binding affinity, convenient routes of administration, and cost effective production

The EBD Group’s 17th annual Bio-Europe Spring Conference was held March 20-22, 2023, in Basel, Switzerland. The conference showcased three thematic pillars – the business of biotech, therapeutic insight tracks, and ecosystem influencers. The elite European bio-tech conference featured a mix of keynotes from life science executives, fireside chats, panel discussions, and presentations that allowed attendees to hear the latest industry trends, insights, exciting opportunities, and challenges. A featured presentation by BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company engaged in developing, manufacturing, and commercializing innovative immunotherapeutic products for infectious and autoimmune diseases,  highlighted the company’s unique approach to developing biobetter therapeutics targeting diseases with underserved medical needs and large commercial opportunities.

After the Bio-Europe Spring Conference ended, NASDAQ published an article with the best ideas from the event – including BiondVax, who shared a stage with top names like Novartis, Bristol Myers Squibb, Pfizer, and Roche. Investors and attendees of the conference gained exceptional insight into the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Photography by Christophe Tomatis
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.